Of interest, comparative analysis of pre- and post-CART19 therapy tissue samples collected from nine patients with high-grade B-cell lymphomas who failed this immunotherapy, revealed not only at least a partial decrease in CD19 expression by eight of the lymphomas but also less frequently seen losses of other B-cell markers CD79A, CD20, and PAX5 (34). Here, CD19 is linked to lymphoma.